AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01511380 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual services
Description: In addition to the standard juvenile drug court requirements, youth randomly assigned to the usual services condition are also ordered to receive treatment services from the local state or privately-funded alcohol and drug treatment provider agencies. The service delivery model for agencies typically includes intensive outpatient, traditional outpatient, and home-based services, depending upon assessment of youth and family needs. Groups focus on risk reduction, peer influence, conflict resolution, and anger management. Additionally, youth might receive treatment pertaining to drug selling behavior, individual sessions and/or family group therapy. The theoretical orientations of the provider agencies are cognitive-behavioral and systems theory. Interventions are not usually manual driven, and selection of material is typically left to the therapists' discretion.
Study NCT00967408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Rehabilitative treatment + Oral Escitalopram 5 mg/day for the first week, 10 mg/day from second to fourth week and 20 mg/day until 6th month.
Study NCT00967408 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rehabilitative treatment + oral inactive placebo for 6 months
Study NCT00967408 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitative treatment
Description: Rehabilitative treatment
Study NCT00967408 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rehabilitative treatment
Description: Rehabilitative treatment
Study NCT00153751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine
Description: They are Common peony root, Rhizoma Atractylodis Macrocephalae, Radix Paeoniae Lactiflorae, Cortex Magnoliae Officinalis, Rhizoma Curcumae Longae, Fructus Schisandrae Chinensis, Pericarpium Citri Reticulatae, and Rhizoma Corydalis Yanhusuo.
Study NCT00153751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Holopon
Description: holopon
Study NCT00153751 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01504074 — intervention group
Intervention type: BEHAVIORAL
Intervention: if needed (decided individually) either Acular eye drops, Ultracortenol eye drop or intravitreal triamcinolone injection
Description: if prescribed: Ultracortenol/ Acular eye drops 3-4 times a day, if prescribed: singular intravitreal triamcinolone injection
Study NCT02163746 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 (carbon dioxide) laser
Study NCT00751088 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TVT secur system positioning
Description: Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. TVT Secur System will be placed by means of two curved, stainless steel, single use introducers. Incision closure.
Study NCT00751088 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ajust positioning
Description: Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. Ajust will be placed by means of a safe hook geometry introducer. Incision closure.
Study NCT02163746 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Deroofing
Study NCT03294382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: 5U botulinum toxin in 0.1 mL normal saline, injected in two points at one side, 2.5U per point, local injection
Study NCT00211081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone (drug)
Description: 1 mg/kg/day; afer 2 weeks doubled to 2/mg/kg/day. Patient's with endothelium-dependent brachial artery vasodilation and single-ventricle should show improvement within 4-8 weeks. Patients and their labs who are receiving Spironolactone will be followed.
Study NCT00402389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acids (EPA plus DHA)
Description: Four capsules will be taken daily for 8 weeks.
Study NCT00402389 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy
Description: Supportive psychotherapy will provide education to increase understanding of the condition, guidance on how to cope with depression, and methods on how to improve self-esteem.
Study NCT00402389 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Supportive psychotherapy
Description: Supportive psychotherapy will provide education to increase understanding of the condition, guidance on how to cope with depression, and methods on how to improve self-esteem.
Study NCT00402389 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Four capsules will be taken daily for 8 weeks.
Study NCT03294382 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.1 mL normal saline, injected in two points at one side, 0.05 mL per point, local injection
Study NCT01150695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline will be administered to all subjects as a control and will be given at the same visit as the vaccine (Day 0).
Study NCT01150695 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Undiluted Francisella tularensis live attenuated vaccine
Description: Undiluted Francisella tularensis live attenuated vaccine \[approximately 1x10\^9 colony forming units (cfu)/mL\] produced by Dynport Vaccine Company. Administered by scarification in the ulnar aspect of the volar surface (palm side) of the forearm midway between the wrist and the elbow.
Study NCT01150695 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Undiluted Francisella tularensis live attenuated vaccine
Description: Undiluted Francisella tularensis live attenuated vaccine (approximately 1x10\^9 cfu/mL) in use by the United States Army Medical Research Institute of Infectious Diseases. Administered by scarification in the ulnar aspect of the volar surface (palm side) of the forearm midway between the wrist and the elbow.
Study NCT00678691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: armodafinil
Description: 50-250mg/d
Study NCT02674568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine
Description: Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC).
Study NCT00678691 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo
Study NCT01689896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Gel
Study NCT01689896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Study NCT02260427 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertion of the i-gel
Description: After induction of general anesthesia, the i-gel will be inserted according to randomly allocated group.
Study NCT02260427 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of the air-Q sp
Study NCT03765307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SyMap Bronchial Ablation System
Description: The Bronchial Ablation is performed using SyMap Bronchial Ablation System in three sessions at least three weeks apart between each session: Right Lung Lobe, Left Lung Lobe, Right Up Lobe and Left Up Lobe.
Study NCT03765307 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Boston Scientific Alair System
Description: The Bronchial Thermoplasty is performed using Boston Scientific Alair System in three sessions at least three weeks apart between each session: Right Lung Lobe, Left Lung Lobe, Right Up Lobe and Left Up Lobe.
Study NCT02017691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near Infrared Spectroscopy
Description: If crSO2 is \<10th centile, CPAP via face mask will be started or oxygen support will be increased depending SpO2, on the infants breathing efforts and the heart rate. If crSO2 remains stable >10th centile, or if crSO2 is > 90th centile CPAP via face mask will be stopped or FiO2 will be reduced depending on SpO2, the infants breathing efforts and the heart rate.
Study NCT02017691 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pulse-oximetry
Description: If SpO2 remains \<10th centile, respiratory support via face mask will be started or FiO2 will be increased depending on the infants breathing efforts and the heart rate. If SpO2 remains stable or if SpO2 is >90th centile respiratory support via face mask will be stopped or FiO2 will be reduced depending on the infants breathing efforts and the heart rate.
Study NCT03623737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant chemoradiation
Description: Neoadjuvant chemoradiation:~1. Radiation: 180cGy/fraction, once daily, 5 days a week, to a total of 4,500cGy.~2. Chemotherapy: Arm A or Arm B Surgery: esophagectomy and 3-fields lymph node dissection
Study NCT03623737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemoradiation
Description: Neoadjuvant chemoradiation:~1. Radiation: 180cGy/fraction, once daily, 5 days a week, to a total of 4,500cGy.~2. Chemotherapy: Arm A or Arm B Surgery: esophagectomy and 3-fields lymph node dissection
Study NCT03552887 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac Surgery
Description: Any type of cardiac surgery
Study NCT03552887 — intervention group
Intervention type: PROCEDURE
Intervention: Physiotherapy
Description: Any type of physiotherapy intervention, performed by physiotherapists outside of the protocol
Study NCT02601040 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Attenuated Hepatitis A Vaccine, H2 Strain
Description: 6.50 lgCCID50/ml in babies aged 18-35 months\\6.50 lgCCID50/ml in children aged 3-16 years \\6.50 lgCCID50/ml in adults aged 17 up to 65 years old
Study NCT02601040 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Hepatitis A Vaccine, Lu8 Strain
Description: 320EU/Vial in babies aged 18-35 months \\320EU/Vial in children aged 3-16 years \\640EU/Vial in adults aged 17 up to 65 years old\\boost at month 6\\two-dose
Study NCT02601040 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Group A Meningococcal Polysaccharide vaccine
Description: 30µg Group A Meningococcal Polysaccharide vaccine in subjects aged 18 months-65 years old
Study NCT04029766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Study NCT02928562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: cyclic exercise, aerobic exercise and resistant training exercise
Study NCT02826239 — intervention group
Intervention type: DEVICE
Intervention: multiple breath washout test (MBW)
Description: measured in upright and supine position
Study NCT01285388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MB12066
Description: MB12066 10mg, 100mg/tab. once oral dose MB12066 10, 30, 100, 150, 200mg
Study NCT01285388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB12066
Description: MB12066 10mg, 100mg/tab. once oral dose MB12066 10, 30, 100, 150, 200mg
Study NCT01285388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MB12066
Description: MB12066 10mg, 100mg/tab. once oral dose MB12066 10, 30, 100, 150, 200mg
Study NCT04285736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Ivabradine (5mg twice daily)
Study NCT04285736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: Ivabradine (5mg twice daily)
Study NCT00654524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gonadotropin-releasing-hormone agonist (GnRHa) - Goserelin
Description: The patient will be managed with GnRH-a injection (Goserelin 3.6mg) every 4 weeks for 6 months plus add-back therapy (Caltrate With Vitamin D 600mg p.o. q.d.\& Livial 1.25-2.5mg p.o. q.d.) if needed.
Study NCT04285736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Study NCT01890200 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: conventional treatment of Hepatitis C
Study NCT01890200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: conventional treatment of Hepatitis C
Study NCT01890200 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: conventional treatment of Hepatitis C
Study NCT01890200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: conventional treatment of Hepatitis C
Study NCT01890200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCM-700C
Description: An add-on drug to conventional treatment of Hepatitis C
Study NCT01890200 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, without acting ingredient.
Study NCT00779766 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV GSK 580299 vaccine
Description: Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
Study NCT00779766 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Subjects were planned to receive three doses of the placebo control administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
Study NCT04416035 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRS003
Description: TRS003 will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W). Each cycle is 3 weeks.
Study NCT04416035 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: China-approved Bevacizumab
Description: China-approved bevacizumab will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W).Each cycle is 3 weeks.
Study NCT04416035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered at an AUC 6 mg/mL/ min (the maximum dose capped at 900 mg) by IV infusion (over 15 - 30 minutes) Q3W on Day 1 of each cycle.
Study NCT04416035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered at an AUC 6 mg/mL/ min (the maximum dose capped at 900 mg) by IV infusion (over 15 - 30 minutes) Q3W on Day 1 of each cycle.
Study NCT04416035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered at a dose of 200 mg/m\^2 by IV infusion (over 3 hours) Q3W on Day 1 of each cycle
Study NCT04416035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered at a dose of 200 mg/m\^2 by IV infusion (over 3 hours) Q3W on Day 1 of each cycle
Study NCT02956213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HEPA portable air filter
Description: A high efficiency (MERV17) portable air filter (HEPA portable air filter) will be placed in the subject's bedroom and will run 24/7 for the duration of the study.
Study NCT02956213 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Control/Active Comparator
Description: A portable air filtering device will be placed with no high-efficiency air filter, but only the basic carbon filter in place. Then at cross over, there will be an active HEPA portable air filter used
Study NCT00651482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study NCT06566391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Nivolumab and Ipilimumab (sequential) for a total of four doses followed by Nivolumab
Study NCT00651482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT02820194 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiation Therapy
Description: Stereotactic body radiation is a therapy for delivering a conformal high dose of radiation to the tumor and a minimal dose to surrounding critical tissues, with a hypofractionation schedule
Study NCT02820194 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microwave Ablation
Description: Microwave ablation (MWA) is a newer technology that utilizes high-frequency electromagnetic radiation to create thermal damage and coagulation necrosis
Study NCT00607945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosiglitazone (Avandia) OR other diabetes medication currently prescribed to participant
Description: Rosiglitazone 4-8mg/day, pill, from week -4 to week 32 OR other diabetes medication taken as prescribed from week -4 to week 32
Study NCT00607945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (Avandia) OR other diabetes medication currently prescribed to participant
Description: Rosiglitazone 4-8mg/day, pill, from week -4 to week 32 OR other diabetes medication taken as prescribed from week -4 to week 32
Study NCT00607945 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: conjugated linoleic acid (CLA)
Description: 3.2 g/day, capsule, week 0 to week 32
Study NCT02263677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 60 day supply of 100mg Sitagliptin. The investigators will use an MRS (a non invasive method using magnets) to evaluate liver fat before and after subjects take a diabetes medication. The investigators will also collect a small amount of blood to measure liver, kidney and hormone functions. This will be done 4 times. Also, at the time of the subject gets their first dose of medication they will have a DEXA (low exposure x-ray often used in clinical practice to measure bone density and body composition).
Study NCT04222218 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: Cerebellar repetitive theta Burst stimulation will be performed as detailed in the Real arm description
Study NCT04222218 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: Cerebellar repetitive theta Burst stimulation will be performed as detailed in the Real arm description
Study NCT00607945 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: conjugated linoleic acid (CLA)
Description: 6.4 g/day, capsule, week 0 to week 32
Study NCT01159301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entinostat
Description: Given orally (PO)
Study NCT01159301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given PO
Study NCT01159301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01159301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02321982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Same-day preoperative consultation
Description: Preoperative consultation occurs on the same day as Mohs surgery
Study NCT04441450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]ICP-022
Description: 150mg suspension containing 100μCi of \[14C\]ICP-022
Study NCT03064126 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RANGER™ Paclitaxel Coated Balloon
Description: A procedure that utilizes a balloon coated with paclitaxel (drug) which can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored. The tube is then removed. The blood vessels that will be treated in the RANGER II SFA study include the superficial femoral arteries and the proximal popliteal arteries.
Study NCT03064126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: The RANGER™ Balloon is coated with the drug Paclitaxel.
Study NCT03064126 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Balloon Angioplasty
Description: A procedure that utilizes an uncoated balloon which can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored. The tube is then removed. The blood vessels that will be treated in the RANGER II SFA study include the superficial femoral arteries and the proximal popliteal arteries.
Study NCT01764776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Description: LDE225
Study NCT04402944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulmozyme
Description: Pulmozyme 2.5 mg BID